Phase II study in patients suffering from metastatic breast cancer Her2neg, The Line, randomized (1:1) with two arms. studio di fase II, in paziente affette da carcinoma della mammella metastatico Her2neg, I linea, randomizzato (1:1)a due bracci evaluate the performance in terms of response rates (RR) and quality of life valutare l'attività in termini di percentuali di risposte (RR) e di qualità di vita

• Country None
• organs None
• Specialty None

Bevacizumab + Folfox4 or Xelox2 as first- line treatment in colorectal cancer. Randomized phase II study To estimate the effectiveness of the combination of Oxaliplatino and Capecitabine (XELOX-2) + bevacizumab measured in terms of objective response rate in non treaty advanced colorectal cancer treatmen...

• Country None
• organs None
• Specialty None

Cisplatin and capecitabine (ECX) in stomach adenocarcinoma()tratment in advanced stage.Multicenter randomized phase II trial foolwed by GOIM. Cisplatino e Capecitabina (ECX) nella terapia dell’adenocarcinoma gastrico in fase avanzata: studio multicentrico randomizzato di fase II del GOIM (Gruppo Oncologico Italia Meridionale) Objective Response Rate (%) valutare l’efficacia della schedule messe a confronto in termini di Response Rate (%)

• Country None
• organs None
• Specialty None

Phase II multicenter study with Fotemustine and Temozolomide modulation in patients with metastatic melanoma (MM) Overall response

• Country None
• organs None
• Specialty None

Optimal strategy in K-ras wild type metastatic colorectal cancer patients: cetuximab plus FOLFIRI followed by FOLFOX+/- cetuximab (GOIM multicenter program) The primary objective of first line treatment is: - Evaluation of efficacy (in terms of PFS) of ongoing FOLFIRI + Cetuximab as first line treatment in wild type (WT) K-ras metastatic colorectal cancer...

• Country None
• organs None
• Specialty None

Xelox-2 in untreated patients with advanced colorectal cancer.A Phase II multicenter study of the gruppo oncologico dell Italia meridionale GOIM 2.1.1 To investigate the efficacy of Oxaliplatin in combination Xeloda in patients with locally advanced or metastatic colorectal cancer, not previously treated with chemotherapy.

• Country None
• organs None
• Specialty None

Trastuzumab, docetaxel and gemcitabine as first line treatment for HER-2 positive advanced breast cancer: a phase II of G.O.I.M To estimate the antitumor activity of the combination of Gemcitabine and Docetaxel plus Trastuzumab in terms of objectives response

• Country None
• organs None
• Specialty None

A phase II study of metronomic oral chemoterapy with Cyclophosphamide plus Capecitabine combined with Trastuzumab in advanced breast cancer To assess the activity in terms of overall clinical benefit, defined as the objective response rate plus the rate of stable disease lasting longer than 24 weeks.

• Country None
• organs None
• Specialty None

RANDOMIZED PHASE II TRIAL OF FIRST LINE CISPLATIN WITH DOCETAXEL OR VINORELBINE FOR 6 CYCLES IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER To assess the antitumor activity and safety of vinorelbine given for six courses in combination with cisplatin versus docetaxel and cisplatin in combination..

• Country None
• organs None
• Specialty None

Paclitaxel + Bevacizumab versus doxorubicina liposomiale non pegilata (Myocet), cyclophosfamide e Bevacizumab as the first line treatment in HER-2 negative metastatic breast cancer. Multicenter randomized Study of phase II PACLITAXEL + BEVACIZUMAB VERSUS DOXORUBICINA LIPOSOMIALE NON PEGILATA (MYOCET®), CICLOFOSFAMIDE E BEVACIZUMAB NEL TRATTAMENTO DI 1a LINEA NEL CARCINOMA MAMMARIO METASTATIZZATO HER-2 NEGATIVO -STUDIO MULTICENTRICO RANDOMIZZATO DI FASE II- to value the activity of chemotherapic combinations in terms of objective response rate Obiettivo primario: valutare l’attività delle combinazioni chemioterapiche in termini di percentuale di ...

• Country None
• organs None
• Specialty None